Viimane versioon :
18/04/2024
Infostab
Ingredientide nimekiri
Nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
Uurimisrühmad
Valistab
Plakat
Sidemed
Sponsorid
Autor
Kasutusjuhend
Ajakiri
Tigecycline
Keemiline struktuur
Kaubanduslikud nimed erinevates maades
Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist
Eticina
Mehhiko
Grexyl
Mehhiko
Linicetil
Mehhiko
Mrsacin
Türgi
Tecygen
Tšiili
Tigecid
Türgi
Tigecilina
Argentiina, Ecuador, Tšiili
Tigecycline
Kanada
Tigetop
Tšiili
Tizoxim
Argentiina
Tygacil
Ameerika ühendriigid, Araabia Ühendemiraadid, Argentiina, Austria, Belgia, Ecuador, Hispaania, Holland, Iirimaa, Island, Itaalia, Jaapan, Kanada, Kolumbia, Kreeka, Luksemburg, Malaisia, Maroko, Mehhiko, Norra, Poola, Portugal, Prantsusmaa, Rootsi, Rumeenia, Saksamaa, Saudi Araabia, Soome, Suurbritannia, Sveits, Taani, Tšiili, Türgi, Ungari, Uus-Meremaa, Venetsueela
Zomiprerin
Maroko
Viited : Tigecycline
Tüüp
Avaldamine
2262
Ajaleht
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128
Labor
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3254
Ajaleht
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332
Labor
Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3531
Labor
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3644
Labor
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3674
Labor
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3827
Plakat
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828
Plakat
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829
Plakat
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3887
Ajaleht
Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P.
Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions.
Perit Dial Int 2016 ; 36:410-414.
4055
Ajaleht
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145
Ajaleht
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528
Ajaleht
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
Mentions Légales
